NCT02243306View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

October 24, 2014

Primary Completion Date

May 10, 2017

Study Completion Date

May 10, 2017

Conditions

Anaemia

Interventions

DRUG

GSK1278863

Round, biconvex, white film coated tablet containing 5 mg GSK1278863.

Trial Locations (2)

55404

GSK Investigational Site, Minneapolis

80228

GSK Investigational Site, Lakewood

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT02243306 - Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis | Biotech Hunter | Biotech Hunter